Health Resources and Services Administration (HRSA)
Health Resources and Services Administration (HRSA) programs aim to provide health care to geographically isolated or economically/medically vulnerable populations. These groups include but are not limited to people who have HIV, pregnant women and mothers, low income families, people who live in rural areas, and Indigenous groups. HRSA also provides support to health infrastructure through the training and distribution of health professionals and the advancement of telehealth. HRSA also oversees programs such as the 340B hospital drug discount program, organ, bone marrow, and cord blood transplantation, vaccination injury compensation, and maintaining data regarding malpractice payments.
In 2024, HRSA provided $11,295,901,925 in grants and cooperative agreements and an additional $491,369,922 in loan repayments and scholarships.
Hospitals participating in HRSA as of 2024 are identified on the Public Health Map. These facilities may be impacted by proposed changes to HRSA's budget and structure.
340B Program
Section 340B (Public Health Service Act) requires that pharmaceutical manufacturers that participate in medicaid sell discounted outpatient drugs to health care organizations that care for uninsured and low-income patients. The 340B program lets hospitals reduce the price of outpatient medications and expand health services for patients. Hospitals may use 340B savings in a variety of ways, such as providing free care for uninsured patients or offering free vaccines.
Changes to HRSA
- The Health Resources and Services Administration will be combined with several other organizations under the Health and Human Services umbrella into a new agency: the Administration for a Healthy America (AHA).
- While President Trump has outlined a $1.73 billion reduction for HRSA for 2026, similar services may be offered through other programs.